Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 174, Issue 6, 1996, Pages 1688-1694

  Cain, J M ^a   Collins, C ^a   Petersdorf, S ^a   Figge, D C ^a   Tamimi, H K ^a   Greer, B E ^a   Livingston, R B ^a   Schlaerth, J B ^a   Golditch, I ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cisplatin; cyclophosphamide; etoposide; ovarian cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; DRUG RESISTANCE; FEMALE; HUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030037730     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(96)70198-9     Document Type: Conference Paper

References (22)

1. L Levin W. Hryniuk Dose intensity analysis of chemotherapy regimens in ovarian carcinoma J Clin Oncol 5 1987 756 757
2. R Ozols Y Ostchega C Meyers RC. Young High dose cisplatin in hypertonic saline in refractory ovarian cancer J Clin Oncol 3 1985 1246 1250
3. RF Ozols JT Thigpen J Dauplat N Colombo MJ Piccart E Bertelsen Advanced ovarian cancer: dose intensity Ann Oncol 4 1993 49 56
4. SA Holden BA Teicher E Frei III. Stable and transient cross-resistance and collateral sensitivity among antitumor alkylating agents Proc Am Assoc Cancer Res 34 1993 268
5. ER Broun JL Belinson JS Berek D McIntosh D Hierd H Bade Salvage therapy for recurrent and refractory ovarian cancer with high dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study Gynecol Oncol 54 1994 142 146
6. KK Fields GJ Elfenbein HM Lazarus BW Cooper JB Perkins RJ Creger Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile J Clin Oncol 13 1995 323 332
7. PJ Stiff RS McKenzi DS Alberts J Sosman J Dolan N Rad Phase I clinical and pharmokinetic study of high dose mitoxantrone combined with carboplatin, cytoxan and autologous bone marrow transplant: high response for refractory ovarian cancer J Clin Oncol 12 1994 176 183
8. EJ Schpall RB Jones AI Bearman MP. Purdy Future strategies for the treatment of advanced epithelial ovarian cancer using high dose chemotherapy and autologous bone marrow support Gynecol Oncol 54 1994 347 361
9. J Dauplat M Legros P Condat JP Ferriere S Ben Ahmed R. Plagne High dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second look operation Gynecol Oncol 34 1989 294 298
10. National Institutes of Health Consensus Development Panel on Ovarian Cancer Ovarian cancer: screening, treatment, and follow-up JAMA 273 1995 491 497
11. B Coiffier P Thierry AK Burnett ML. Symann Consensus conference on intensive chemotherapy plus hematopoietic stem-cell transplantation in malignancies J Clin Oncol 13 1994 226 231
12. C Collins J Cain RB. Livingston High dose cyclophosphamide, VP-16 and cisplatin (CEP) does not require bone marrow infusion Proc Am Soc Clin Oncol 10 1991 107
13. JA Neidhart W Kohler C Stidley A Mangalik A Pauche T Anderson Phase I study of repeated cycles of high dose cyclophosphamide, etoposide and cisplatin administered without bone marrow transplantation J Clin Oncol 8 1991 1728 1738
14. SD Huan JC Yau FR Dunphy RO Wallerstein K Dicke V Spencer Impact of autologous bone marrow infusion on hematopoietic recovery after high dose cyclophosphamide, etoposide and cisplatin J Clin Oncol 9 1991 1609 1617
15. P Viens D Maraninchi M Legros T Oberling T Philip P Herve High dose melphalan and autologous marrow in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France Bone Marrow Transplant 5 1990 227 233
16. EJ Schpall D Clarke-Pearson JT Soper A Berchuck RB Jones RC. Bast High dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer Gynecol Oncol 38 1990 386 391
17. TC Shea JR Mason AM Storniolo B Newton M Breslin JM Mullen Sequential cycles of high dose carboplatin administered with recombinant GM CSF and repeated infusions of A peripheral blood progenitor cells: a novel and effective method for delivering multiple courses of dose intensive therapy J Clin Oncol 10 1992 464 473
18. P Stiff R Bayer J Sosman D Peace J Dolon R. Potkul Platinum sensitivity and how tumor burdens are of prognostic significance in patients undergoing an ABMT for advanced cancer Proceedings of the annual meeting of the Society for Gynecologic Oncology, San Francisco, California, February 18-22, 1995 1995 The Society San Francisco
19. Y Ben David B Rosen T Einarson I. Zeiler Meta-analysis comparing cisplatin total dose intensity to survival (SGO abstract) Gynecol Oncol 56 1995 138
20. A Covens A Berchuck M Carney S LoCoco E Franssen D. Clarke-Pearson Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study [abstract] Gynecol Oncol 56 1995 128
21. M Bruzzone A Gadducci S Brunetti Mammoliti L Iskra E Chiara Prognostic factors affecting long term survival of advanced ovarian cancer (AOC) patients (pts.): univariate and multivariate analysis at 12 years follow up Proc Am Soc Clin Oncol 14 1995 286
22. GK Ellis RB Livingston J Lechner E Feldman S Petersdorf A Kalisiak Adjuvant high dose cyclophosphamide, etoposide and cisplatin (CEP) not requiring stem cell rescue for high risk localized breast cancer Proc Am Soc Clin Oncol 14 1995 124